A systematic literature review of clinical trials and therapeutic applications of ibogaine

Köck and colleagues frame iboga, ibogaine, and noribogaine as indole alkaloids of growing scientific interest because of reported ‘‘anti-addictive’’ properties and distinct psychoactive and somatic effects that differ from classical hallucinogens. Earlier research, largely preclinical and observational, has suggested potential efficacy in opioid use disorder (OUD), cocaine use disorder (CUD) and other substance use disorders (SUDs), but controlled clinical evidence remains scarce and safety concerns—particularly cardiotoxicity and several fatal cases—have been repeatedly reported. Regulatory approaches and clinical guidance vary internationally, and the mechanisms underlying therapeutic effects are not fully characterised. This systematic review set out to identify all human studies of ibogaine or noribogaine with investigative or therapeutic intent published up to 7 December 2020, and to summarise effectiveness and safety outcomes. The authors aimed to update prior reviews by applying PRISMA-guided searches of PubMed and EMBASE, synthesising clinical trials, open-label studies, observational reports, case series and case reports to assess what clinical data exist on efficacy, subjective effects, pharmacology and adverse events.

The investigators conducted a systematic literature search using PubMed and EMBASE with keywords combining ‘‘iboga’’/‘‘ibogaine’’/‘‘noribogaine’’ and terms related to withdrawal, addiction, dependence, specific substances (heroin, opioid, cocaine, alcohol, cannabis, tobacco) and treatment/therapy. Searches covered the literature up to 7 December 2020 and followed PRISMA guidelines. The team considered a broad set of publication types, including peer-reviewed articles, case reports, case series, book chapters and indexed abstracts. Eligibility criteria included any human study design in which iboga, ibogaine or noribogaine were administered for investigative or therapeutic purposes. Outcomes of interest were substance use and SUD symptoms, depressive or trauma-related symptoms, and safety endpoints. Two independent reviewers (PK, KF) screened records and extracted data; a third reviewer (KD) adjudicated disagreements. Extracted items included study type and setting, sample size and demographics, dose and route, concomitant medications, safety measures and principal outcomes. The authors report that heterogeneity in measures and designs precluded statistical pooling, so synthesis was descriptive and narrative. Selection flow as reported: database searches initially identified 1,038 records plus four additional records from other sources. After duplicate removal 743 records remained for screening; 710 were excluded (largely preclinical or animal studies), 33 full texts were assessed and ultimately 24 studies met the inclusion criteria for the qualitative synthesis. The review encompassed a mix of designs: case reports/case series, retrospective/observational studies, open-label trials and double-blind, placebo-controlled clinical trials (including randomized trials). The extracted text does not clearly report a formal risk-of-bias assessment method for included studies.

The review included 24 human studies comprising a total of 705 individuals who received ibogaine or noribogaine. Study types were heterogeneous: seven case reports or case series, eight observational or retrospective studies, six open-label clinical trials and three double-blind, placebo-controlled clinical trials (two of which were randomized). The majority of participants were treated for SUDs: at least 379 individuals (53.8%) for OUD and at least 164 (23.3%) for CUD, with the remainder treated for mixed or unspecified substance problems or other indications. Efficacy signals: Across multiple open-label and observational reports, administration of ibogaine or noribogaine was associated with immediate reductions in opioid withdrawal symptoms (OWS) and decreased craving for opioids or cocaine, often measured with structured instruments (for example HCQ, CCQ, MCCS). Mash and colleagues reported reductions in heroin and cocaine craving and decreased depressive symptoms (Beck Depression Inventory, BDI) in several open-label samples, including a larger study of n=191 showing significant reductions at discharge and at one-month follow-up on craving scales, BDI and mood-state measures. A Brazilian double-blind placebo-controlled trial (n=20) administering a single 1,800 mg dose of ibogaine found a significant reduction in the Minnesota Cocaine Craving Scale (MCCS) at 72 hours and at 24 weeks post-dose, and fewer relapses by urine testing in the ibogaine group. Two randomized trials of noribogaine assessed ascending single doses; one reported no acute safety issues, while the other observed a dose-dependent QTc prolongation (reported as 0.17 ms per ng/mL). Noribogaine trials showed trends toward reduced withdrawal ratings (SOWS, OOWS, COWS) that did not reach statistical significance in the extracted text. Pharmacokinetics and subjective effects: Single oral ibogaine doses reported in older studies generally ranged 500–800 mg; plasma Cmax values for ibogaine were reported between 30–1,250 ng/mL and for noribogaine between 700–1,200 ng/mL, with Tmax around 2 hours for ibogaine and 5 hours for noribogaine. Interindividual variability was high and CYP2D6-mediated hepatic metabolism was implicated; CYP2D6 inhibition (for example with paroxetine) increased AUC and Cmax and prolonged availability. Noribogaine displayed a t1/2 of about 24–30 hours in one study. Subjective effects have been characterised in three phases: an initial oneiric ‘‘waking dream’’ phase (4–8 hours), a reflective evaluative phase (8–20 hours), and a residual phase lasting up to 72 hours; some reports describe intense psychedelic-type experiences and autobiographical insights. Safety and adverse events: Among the 24 included studies, two fatalities were reported. One fatality occurred following informal nonmedical treatment in 1990 with possible concomitant heroin use; the second occurred more recently in a medical setting and was associated with inadequate monitoring, unusually high dosing and cessation of venlafaxine. Additional serious adverse events reported in included studies included bradycardia and prolonged QT interval requiring intensive care transfer. Outside the included dataset the authors identified another 56 ibogaine-associated deaths or emergencies that did not meet inclusion criteria; after cross-checking duplicates they report a total of 58 additional ibogaine-associated emergencies/deaths (20 emergencies and 38 deaths). Cardiac arrhythmias and QT prolongation—likely via hERG channel blockade—were commonly implicated. Reported acute adverse symptoms ranged from nausea, tremor and ataxia to seizures, coma, pulmonary difficulties, mania and psychosis. Some small studies of low or cumulative dosing reported good tolerability, but completion rates varied (for example one noribogaine trial had only four of nine completers). Anecdotal and small-case reports suggest microdosing regimens have been used successfully in some individuals, but systematic evidence is lacking.

The study team interprets the assembled literature as indicative of potential therapeutic benefit of ibogaine and noribogaine for aspects of SUD treatment, specifically rapid reduction of opioid withdrawal symptoms and short-to-medium-term decreases in opioid and cocaine craving. Several included studies also reported reductions in depressive symptoms and improvements in trauma-related symptoms that persisted for weeks to months in some participants. The authors note mechanistic plausibility based on multireceptor interactions (for example SERT, DAT, opioid and sigma receptors), NMDA antagonism, pharmacochaperone activity and possible upregulation of neurotrophic factors such as GDNF, but they emphasise that mechanisms remain incompletely understood. At the same time the researchers emphasise substantial safety concerns: cardiotoxicity (QT prolongation and arrhythmia risk), neuropsychiatric adverse events and a non-negligible number of fatalities reported in the wider literature. They highlight pharmacokinetic variability linked to CYP2D6 metabolism and drug–drug interactions (for example with SSRIs) as clinically important contributors to risk. Given the predominance of case reports, open-label series and retrospective analyses in the body of evidence, the authors caution against strong efficacy conclusions and note that heterogeneity in outcome measures prevented meta-analysis. Consequently, they call for rigorously designed clinical trials performed in well-monitored medical settings, with careful attention to dosing strategies (including exploration of repeated lower doses), pre-treatment assessment of cardiac risk and concomitant medication management, and standardised outcome measures. The authors also point out regulatory inconsistency between countries and propose that standardised clinical guidelines and improved public and clinician awareness could reduce preventable adverse events. Limitations explicitly acknowledged include the heterogeneity of included studies, lack of statistical pooling, and variable reporting quality across reports.

The authors conclude that existing clinical data suggest potential therapeutic effects of ibogaine and noribogaine for SUDs, but that uncertainty remains because most evidence derives from non-randomised and observational designs. They recommend future rigorously designed studies, ideally in medically supervised settings, that explore lower repeated dosing regimens to reduce adverse-event risk, incorporate rapid intervention strategies, and apply standardised monitoring and reporting. Greater clinical and public awareness, together with standardised medical guidance, may help prevent avoidable fatalities and support safer scientific investigation.